0000899243-21-023878.txt : 20210615
0000899243-21-023878.hdr.sgml : 20210615
20210615164122
ACCESSION NUMBER: 0000899243-21-023878
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210611
FILED AS OF DATE: 20210615
DATE AS OF CHANGE: 20210615
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BATE KENNETH
CENTRAL INDEX KEY: 0001210238
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35945
FILM NUMBER: 211019033
MAIL ADDRESS:
STREET 1: C/O MILLENNIUM PHARMACEUTICALS INC
STREET 2: 40 LANDSDOWNE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Epizyme, Inc.
CENTRAL INDEX KEY: 0001571498
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 261349956
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 400 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-229-5872
MAIL ADDRESS:
STREET 1: 400 TECHNOLOGY SQUARE
STREET 2: 4TH FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-11
0
0001571498
Epizyme, Inc.
EPZM
0001210238
BATE KENNETH
C/O EPIZYME, INC., 400 TECHNOLOGY
SQUARE, 4TH FLOOR
CAMBRIDGE
MA
02139
1
0
0
0
Common Stock, par value $0.0001
2021-06-11
4
A
0
8060
0.00
A
8060
D
Stock Option (Right to Buy)
8.53
2021-06-11
4
A
0
40559
0.00
A
2031-06-10
Common Stock
40559
40559
D
Consists of shares of Common Stock issuable under 8,060 restricted stock units ("RSUs") granted on June 11, 2021, which RSUs are scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. Each RSU represents the right to receive one share of Common Stock upon vesting. In the event of a change in control of the Issuer, the RSUs will vest in full.
This option was granted on June 11, 2021 and is scheduled to vest with respect to all shares on the first anniversary of the grant date or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director. In the event of a change in control of the Issuer, the option will become exercisable in full.
/s/ John Weidenbruch, attorney-in-fact
2021-06-15